Safe, straightforward procedure with proven clinical results
in treatment-resistant hypertension patients:
1,2
• Over 2000 clinical and commercial patients treated to date
• No evidence of vascular injury/stenosis at treatment site by
imaging at 6 months
• Sustained renal function (eGFR and creatinine) with no
orthostatic or electrolyte disturbances
• SYMPLICITY HTN-2: 106-patient randomised study proving
treatment effect vs. medical management
• SYMPLICITY HTN-1: 153 patients enrolled in a series of
nonrandomised studies show durable results to 2 years
1
Significant and sustained blood
pressure reductions
Introducing the Symplicity
TM
Renal
Denervation System:
1
SYMPLICITYHTN-1 Investigators.Catheter-basedrenalsympatheticdenervation forresistanthypertension:
durabilityofbloodpressurereductionoutto24months.
Hypertension.
2011;57:911–917.
2
SYMPLICITYHTN-2 Investigators.Renalsympatheticdenervation inpatientswithtreatment-resistant
hypertension (theSymplicityHTN-2trial):arandomisedcontrolledtrial.
TheLancet.
2010;376:1903–1909.
Symplicity isatradmarkofMedtronic, Inc.and isregistered inoneofmorecontriesoftheworld.
Not fordistribution intheUSAorJapan.©2012Medtronic, Inc.Allrightsreserved.UC201205084EE 2/12
Six-Month Change in Blood Pressure
2
Control (n = 51)
Renal denervation (n = 49)
0
-10
-20
-30
-40
1 0
Systolic
Diastolic
Innovating for life.
